The estimated Net Worth of Christopher Patusky is at least $4.24 Миллион dollars as of 3 September 2024. Mr. Patusky owns over 5,000 units of United Therapeutics Corp stock worth over $1,800,188 and over the last 20 years he sold UTHR stock worth over $1,944,471. In addition, he makes $496,604 as Lead Independent Vice Chairman of the Board at United Therapeutics Corp.
Christopher has made over 94 trades of the United Therapeutics Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of UTHR stock worth $877,150 on 3 September 2024.
The largest trade he's ever made was exercising 9,000 units of United Therapeutics Corp stock on 12 January 2011 worth over $244,350. On average, Christopher trades about 2,822 units every 62 days since 2005. As of 3 September 2024 he still owns at least 5,200 units of United Therapeutics Corp stock.
You can see the complete history of Mr. Patusky stock trades at the bottom of the page.
Prof. Christopher Patusky J.D. serves as Lead Independent Vice Chairman of the Board of the Company. After graduating from Harvard Law School, he clerked and practiced law from 1988 to 2000, focusing on litigation, intellectual property, and business startups. After receiving a master's degree in governmental administration from the University of Pennsylvania, Mr. Patusky served from 2002 to 2007 as the Executive Director and as a member of the faculty of the University of Pennsylvania's Fels Institute of Government. From 2007 to 2011, he served as the Director of the Office of Real Estate and as a member of the Senior Policy Team at the Maryland Department of Transportation, staying on in a part-time capacity until 2013. Since 2012, Mr. Patusky has served as the founding principal of Patusky Associates, LLC, which serves as a personal investment vehicle, and as an executive manager of Slater Run Vineyards, LLC, his family's farm-based vineyard and winery. Our Board of Directors has determined that Mr. Patusky meets the financial sophistication requirements of Nasdaq's listing standards. He has served as a United Therapeutics director since 2002.
As the Lead Independent Vice Chairman of the Board of United Therapeutics Corp, the total compensation of Christopher Patusky at United Therapeutics Corp is $496,604. There are 10 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.
Christopher Patusky is 57, he's been the Lead Independent Vice Chairman of the Board of United Therapeutics Corp since 2007. There are 10 older and 7 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli и Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: